Vibegron
- TRADE NAME: Gemtesa (Urovant)
- INDICATIONS:
Treatment of an overactive bladder
- CLASS: Beta-3 adrenergic agonist
- HALF-LIFE: approximately 31 hours
FDA APPROVAL DATE: 12/23/2020
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:No available data to evaluate drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
Clinical trials of vibegron were conducted in patients with an overactive bladder, the majority of whom were Caucasian (78%) and female (85%) with a mean age of 60 years (range 18 to 93 years).
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric